Equity Overview
Price & Market Data
Price: $2.59
Daily Change: +$0.125 / 4.84%
Range: $2.47 - $2.68
Market Cap: $4,238,159
Volume: 11,978
Performance Metrics
1 Week: -2.43%
1 Month: 61.73%
3 Months: 27.70%
6 Months: 20.60%
1 Year: -76.10%
YTD: 36.75%
Company Details
Employees: 1
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.